Arrowhead (ARWR) announced that it submitted a new drug application, or NDA, to the FDA for investigational plozasiran for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback